Results 71 to 80 of about 186,128 (186)

Real-world short-term outcomes after switching to fixed-interval anti-VEGF therapy for neovascular AMD during the COVID-19 pandemic

International Journal of Retina and Vitreous
Purpose To assess short-term real-world visual and anatomic outcomes in patients with neovascular age-related macular degeneration (nvAMD) following a protocol shift from an individualized treat-and-extend (T&E) anti-VEGF regimen to a fixed-interval ...
Arnulfo Garza Reyes, Tirth J. Shah, Edward F. Linton, Zachary Q. Mortensen, Timothy M. Boyce, Aaron M. Ricca, Razek G. Coussa, H. Culver Boldt, James C. Folk, Stephen R. Russell, Ian C. Han, Karen M. Gehrs, Elliott H. Sohn   +12 more
doaj   +1 more source

Review of Guideline Recommendations for Optimal Anti-VEGF Therapy in Age-Related Macular Degeneration

Life
Neovascular age-related macular degeneration is a progressive, blinding macular disease that has become a burden both in healthcare systems and the global economy. The vascular endothelial growth factor (VEGF) is the main agent involved in the pathogenic
Andreea Dana Moraru, Ciprian Danielescu, Raluca Eugenia Iorga, Radu Lucian Moraru, Mihail Zemba, Daniel Constantin Branisteanu   +5 more
doaj   +1 more source

Treat and extend compared to pro re nata regimen in neovascular age-related macular degeneration

Medwave, 2020
Age-related macular degeneration is the leading cause of blindness in older people in the world. One of the most effective treat-ments consists of injection intravitreal of anti-endothelial vascular growth factor (anti-VEGF) drugs. However, there is no con-sensus on their frequency of administration, being the treat and extend and the pro re nata the ...
Rodolfo, Garretón, Raúl, González
openaire   +3 more sources

Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema. [PDF]

, 2016
PURPOSE To compare outcomes between an as-needed and a treat-and-extend regimen in managing diabetic macular edema with intravitreal ranibizumab. METHODS This was a retrospective, single-centre, comparative case series on 46 treatment naive ...
Ebneter, Andreas, Waldmeier, Dominik, Wolf, Sebastian, Zinkernagel, Martin, Zysset-Burri, Denise Corinne   +4 more
core   +1 more source

Initiation and maintenance of a Treat-and-Extend regimen for ranibizumab therapy in wet age-related macular degeneration: recommendations from the UK Retinal Outcomes Group

Clinical Ophthalmology, 2018
Winfried Amoaku,1 Konstantinos Balaskas,2,3 Tomas Cudrnak,4 Louise Downey,5 Markus Groppe,6 Sajjad Mahmood,7 Hemal Mehta,8 Quresh Mohamed,9 Bushra Mushtaq,10 Philip Severn,11 Athanasios Vardarinos,12 Yit Yang,13 Saad Younis14 1Academic Ophthalmology ...
Amoaku W, Balaskas K, Cudrnak T, Downey L, Groppe M, Mahmood S, Mehta H, Mohamed Q, Mushtaq B, Severn P, Vardarinos A, Yang Y, Younis S   +12 more
doaj  

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration [PDF]

, 2019
Objective: To evaluate the functional and anatomical response after the switch from bevacizumab to aflibercept in treatment-resistant wet age-related macular degeneration (wAMD) using the treat-and-extend regimen protocol.
Laine, Ilkka, Taipale, Claudia, Tuuminen, Raimo   +2 more
core   +1 more source

Aflibercept treatment for neovascular AMD beyond the first year: consensus recommendations by a UK expert roundtable panel, 2017 update

Clinical Ophthalmology, 2017
Praveen J Patel,1 Helen Devonport,2 Sobha Sivaprasad,1 Adam H Ross,3 Gavin Walters,4 Richard P Gale,5 Andrew J Lotery,6 Sajjad Mahmood,7 James S Talks,8 Jackie Napier9 1National Institute for Health Research Biomedical Research Centre at Moorfields Eye ...
Patel PJ, Devonport H, Sivaprasad S, Ross AH, Walters G, Gale RP, Lotery AJ, Mahmood S, Talks JS, Napier J   +9 more
doaj  

Real-World Outcomes of Switching to Faricimab in Treatment-Experienced and Resistant Neovascular Age-Related Macular Degeneration: A Single-Centre Retrospective Study

Clinical Ophthalmology
Christopher Stewart,1 Jaskaran Singh Bhangu,2 Parinita Keshav Swarnkar,2 Mohammed Rifat,2 Sarah Khalid,2 Ahmed Al-Janabi,2 Mahmoud H Awad,2 Gwyn Samuel Williams2 1Faculty of Medicine, Health, and Life Science, Swansea University, Swansea, Wales, UK ...
Stewart C, Bhangu JS, Swarnkar PK, Rifat M, Khalid S, Al-Janabi A, Awad MH, Williams GS   +7 more
doaj  

Neovascular Age-Related Macular Degeneration Treated with Aflibercept: Five-Year Follow-Up and Correlation with Optical Coherence Tomography Biomarkers in a Real-World Setting

Ophthalmology and Therapy
Introduction To evaluate long-term outcomes of neovascular age-related macular degeneration(nAMD) treatment with aflibercept in a treat-and-extend (T&E) regimen and explore correlations between optical coherence tomography (OCT) biomarkers and clinical ...
Massimiliano Borselli, Mutasem Elfalah, Teresa Angela Trunfio, Arianna Scala, Domenico Chisari, Alessandra Mancini, Andrea Lucisano, Giovanna Carnovale-Scalzo, Vincenzo Mollace, Giovanni Improta, Sandrine Zweifel, Vincenzo Scorcia, Mario Damiano Toro, Adriano Carnevali   +13 more
doaj   +1 more source

Clinical outcomes of a treat-and-extend regimen with intravitreal aflibercept injections in patients with choroidal neovascularization secondary to chronic central serous chorioretinopathy

Journal of Ophthalmology
Purpose: To evaluate 12-month clinical outcomes of a treat-and-extend regimen with intravitreal aflibercept injections in patients with occult (type 1) choroidal neovascularization (CNV) secondary to chronic central serous chorioretinopathy (CSC ...
T. B. Kustryn, O. S. Zadorozhnyy, I. O. Nasinnyk, A. O. Nevska, N. V. Pasyechnikova, A. R. Korol   +5 more
doaj   +1 more source